Argent Biopharma’s (RGT) flagship CannEpil cannabis drug is set to pivot into the veterinary market, just weeks after it signed away the commercial rights in exchange for debt relief.
Last month, Business of Cannabis reported that Argent (previously MGC Pharmaceuticals), had signed a US$5.5m debt-for-equity licensing deal with Splash Beverage Group, handing it the responsibility for development and regulatory approval of CannEpil in new markets, with a focus on the United States.
That original agreement, dated July 6, 2026, covered CannEpil’s human epilepsy programme, before Splash inserted an amendment on July 27 adding veterinary rights to the deal.
Days later (August 05), Splash announced a new development…